Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-tolDC vaccine in multiple sclerosis
NCT02618902Phase 1Completed
- Start
- May 2017
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple sclerosis (MS). Primary endpoints: Occurrence and severity of adverse events at 6 months and Generation of GMP-grade cell product released according to QC at 6 months. Started May 2017; status: completed.
02
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02618902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618902.